Pharma Focus Asia

Japan-based Takeda Pharmaceutical invests $25m in drug discovery firm BioMotiv


BioMotiv and Takeda Pharmaceutical Company has entered into Strategic Partnership,where Takeda has made a initial investment of $25million in BioMotiv.


This partnership will leverage the strengths of both organizations to identify and develop pioneering medical innovations.

The $25 million investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of Immunology & Inflammation and Cardio-metabolic Diseases.

Specifications Table:

  • Company Name
  • Takeda Pharmaceutical
  • Company Invested In
  • BioMotiv
  • Location
  • Cleveland, Ohio
  • Date of Completion
  • 2019
  • Estimated Cost
  • $25 million
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference